Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1599

Shown on this page

Current sort

Stored official records

Conditions: Peri-implantitis
Interventions: Resective surgery with implantoplasty, Resective surgery with mechanical debridement; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bronchiolitis Acute
Interventions: High-Resource Implementation Strategy, Moderate-Resource Implementation Strategy; Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 0 Months to 24 Months
Enrollment: 2,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 60
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more

Conditions: Hyperinflammatory Syndromes, Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 2
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Maternal Death, Severe Maternal Morbidity
Interventions: Doula, Medicaid healthcare quality interventions (incentive payment and obstetric bundled payment), Standard Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 10,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Analgesia, Cardiac Surgery
Interventions: Not listed
Lead sponsor: Kathirvel Subramaniam; Other
Eligibility: 60 Years to 110 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Malignant Neoplasm in the Brain
Interventions: Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery; Procedure · Other · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 208
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more

Conditions: Cesarean Section Complications, Opioid Use
Interventions: Preoperative Genotyping; Diagnostic Test
Lead sponsor: Senthil Sadhasivam; Other
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Indianapolis, Indiana • St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: PPAP, Spine Fusion
Interventions: Preoperative Genotyping; Diagnostic Test
Lead sponsor: Senthil Sadhasivam; Other
Eligibility: 10 Years to 21 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: San Francisco, California • St. Petersburg, Florida • Indianapolis, Indiana + 1 more

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more

Conditions: Aorta; Lesion, Aortic Aneurysm, Thoracic
Interventions: GORE® TAG® Thoracic Branch Endoprosthesis; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 35
States / cities: Los Angeles, California • Stanford, California • Hartford, Connecticut + 29 more

Conditions: Aorta, Lesion, Aortic Aneurysm, Thoracic
Interventions: GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure; Device · Procedure
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 34
States / cities: Los Angeles, California • Stanford, California • Hartford, Connecticut + 28 more

Conditions: Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 8
States / cities: Duarte, California • South Pasadena, California • Chicago, Illinois + 5 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Stored official records

Peri-implantitis Management: Surgical and Maintenance Outcomes

I-DECIDE After Bronchiolitis Hospitalization

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

The Effects of Medicaid Policy Interventions on Severe Maternal Morbidity

Precision Analgesia for Cardiac Surgery

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Personalized Perioperative Analgesia Platform (PPAP) for Cesarean Section

Personalized Perioperative Analgesia Platform (PPAP) for Pediatric Spine Fusion Surgery (sIRB)

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

About this UPMC (University of Pittsburgh) institution page